In vivo behavioral pharmacologist with over 15 years small molecule drug discovery experience spanning from target identification and validation through both non-GLP ADME and GLP IND-enabling Tox efforts in mice, rat, rabbit, dog and NHP. Expertise in establishing and coordinating in vivo pharmacodynamic assays; experienced in managing ADME-PK studies and elucidation of PK-PD relationships. Utilization of tolerability screening to drive early SAR resulting in fewer late-stage surprises and failures in toxicology studies. Extensive hands-on experience managing internal research and external CRO partner relationships involving indirect management and coordination of multiple teams within and outside the organization to best utilize the strength of each team while adhering to target deadlines and regulatory submission dates in the most cost-effective manner. Experienced in training and standardizing of procedures across groups and locations, whether in person or virtual, to ensure robust and reliable results in vivo. Authoring of reports and regulatory documents in support of IND submission.Specializing in animal models of psychiatric and neurodegenerative disorders, pain and neuroinflammation with extensive hands on experience in animal model establishment and characterization for use in compound screening and drug development. Small molecule drug discovery, exploratory biomarker development, non-GLP and GLP IND and NDA-enabling studies, IACUC.